<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882739</url>
  </required_header>
  <id_info>
    <org_study_id>Arezzo002</org_study_id>
    <secondary_id>EUDRACT 2009-010295-23</secondary_id>
    <nct_id>NCT00882739</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Three Different Loading Doses of Clopidogrel, in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>Load &amp; Go</acronym>
  <official_title>Safety and Efficacy of Three Different Loading Doses of Clopidogrel, Administered at First Medical Contact in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. The LOAD &amp; GO Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale San Donato</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine both safety and effectiveness of three different
      loading dose regimens of clopidogrel in patients with acute myocardial infarction undergoing
      primary angioplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll STEMI patients, who were planned to undergo PCI, and will randomize
      them to three different clopidogrel loading dose regimens at first medical contact: no
      pre-treatment, 600 mg or 900 mg. Platelet activity after administration of clopidogrel will
      be evaluated by VerifyNow™ P2Y12 point-of-care system.

      The study is powered to demonstrate significant differences in the primary end point (the
      rate of TIMI Myocardial Perfusion Grade=3).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TIMI Myocardial Perfusion Grade (TMPG)</measure>
    <time_frame>post-PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TIMI flow</measure>
    <time_frame>pre- and post-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected TIMI Frame Count (cTFC)</measure>
    <time_frame>post-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleedings</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACEs)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactive Units (PRU) as assessed by VerifyNow™ System</measure>
    <time_frame>pre-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI 2-3 grade flow of the infarct-related artery</measure>
    <time_frame>pre-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>no reflow phenomenon</measure>
    <time_frame>post-PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>no pre-treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No pre-treatment at first medical contact - Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg clopidogrel loading dose at first medical contact</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900 mg loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg clopidogrel loading dose at first medical contact</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 300 mg</intervention_name>
    <description>Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting</description>
    <arm_group_label>no pre-treatment</arm_group_label>
    <other_name>Plavix-®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 600 mg</intervention_name>
    <description>Patients will receive a 600 mg clopidogrel loading dose at first medical contact</description>
    <arm_group_label>600 mg loading dose</arm_group_label>
    <other_name>Plavix-®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 900 mg</intervention_name>
    <description>Patients will receive a 900 mg clopidogrel loading dose at first medical contact</description>
    <arm_group_label>900 mg loading dose</arm_group_label>
    <other_name>Plavix-®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST-elevation myocardial infarction:

               -  chest pain lasting more than 30 minutes

               -  not responsive to nitrates

               -  ST-segment elevation of more than 0.1 mV in two or more leads on the ECG, or new
                  Left Bundle Branch Block

          -  With indication to primary PCI, presenting within 12 hour from symptoms onset

          -  Age &gt; 18 years

          -  Planned PCI

          -  Informed Consent

        Exclusion Criteria:

          -  bleeding diathesis

          -  allergy to study drugs

          -  pregnancy

          -  the performance of a rescue PCI after thrombolysis

          -  known existence of a disease resulting in a life expectancy of &lt;6 months

          -  lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo Bolognese, MD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Donato</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Ducci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Donato</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Department, Ospedale S.Donato</name>
      <address>
        <city>Arezzo</city>
        <state>AR</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <last_update_submitted>January 25, 2012</last_update_submitted>
  <last_update_submitted_qc>January 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Donato</investigator_affiliation>
    <investigator_full_name>Leonardo Bolognese</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>angiography</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <keyword>Platelet Function Tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

